Gusacitinib hydrochloride is under clinical development by Libertas Bio and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Gusacitinib hydrochloride’s likelihood of approval (LoA) and phase transition for Hand Dermatitis took place on 26 Oct 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Gusacitinib hydrochloride Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Gusacitinib hydrochloride overview

Gusacitinib hydrochloride (ASN-002) is under development for the treatment of hand dermatitis, atopic dermatitis, chronic dermatitis and systemic lupus erythematosus. The drug candidate is administered orally as a tablet. The drug candidate acts by targeting spleen tyrosine kinase (SYK) and Janus kinase (JAK).

The drug candidate was also under development for the treatment of rheumatoid arthritis, relapsed/refractory non-Hodgkin lymphomas including follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia, myelofibrosis, multiple myeloma, erythroleukemia, bladder cancer and Peripheral T-Cell Lymphomas (PTCL).

Quick View Gusacitinib hydrochloride LOA Data

Report Segments
  • Innovator
Drug Name
  • Gusacitinib hydrochloride
Administration Pathway
  • Oral
Therapeutic Areas
  • Dermatology
  • Immunology
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.